Should novobiocin be clinically re-evaluated?
The current novobiocin spectrum of antimicrobial activity was evaluated by testing 585 staphylococci (393 oxacillin-resistant) and 779 other bacterial strains. Novobiocin inhibited 98.5% of all staphylococcal isolates (MIC 90, 0.25 micrograms/ml) and a significant number of other Gram-positive species at less than or equal to 1 microgram/ml. Pathogenic Neisseria, Haemophilus influenzae, and Branhamella catarrhalis were also very susceptible to novobiocin, e.g., MIC 100, less than or equal to 1 microgram/ml. These results indicate that novobiocin may have a role in contemporary chemotherapy of oxacillin-resistant staphylococcal and other infections.
Jones
R N
RN
Clinical Microbiology Institute, Tualatin, Oregon.
D001424:Bacterial Infections / Q000188:drug therapy; D004351:Drug Resistance; D006094:Gram-Positive Bacteria / Q000187:drug effects; D006801:Humans; D008826:Microbial Sensitivity Tests; D009675:Novobiocin / Q000627:therapeutic use*; D010068:Oxacillin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects
D009675:Novobiocin; D010068:Oxacillin